Elsevier

Brain Research

Volume 1055, Issues 1–2, 7 September 2005, Pages 186-195
Brain Research

Research Report
Cocaine self-administration and locomotor activity are altered in Lewis and F344 inbred rats by RTI 336, a 3-phenyltropane analog that binds to the dopamine transporter

https://doi.org/10.1016/j.brainres.2005.07.012Get rights and content

Abstract

Lewis and Fischer 344 (F344) rats differ in responses to cocaine and characteristics of the mesolimbic dopamine system. Compared to F344 rats, Lewis rats have lower D2 receptor and dopamine transporter (DAT) levels in nucleus accumbens (NAc). We showed previously that altering D1 and D2 receptor levels pharmacologically had strain-dependent effects on cocaine self-administration. This study tests whether the phenyltropane analog, 3β-(4-Chlorophenyl) tropane-2β-[3-(4′-methylphenyl) isoxazol-5-yl] Hydrochloride (RTI 336), a potent and selective DAT inhibitor, differentially alters reinforcing, discriminative, and locomotor effects of cocaine in these strains. The effects of RTI 336 pretreatment on cocaine self-administration were assessed under a fixed-ratio (FR) schedule of reinforcement. Its effects on cocaine discrimination were conducted using a two-lever food-reinforced task. Finally, the effects of RTI 336 pretreatment on cocaine-induced locomotor activity were examined. RTI 336 increased cocaine self-administration in F344 rats, while Lewis rats showed reduced intake under the FR schedule. RTI 336 reduced cocaine-induced locomotor activity in Lewis rats but not in F344 rats. RTI 336 did not substitute for or antagonize cocaine's discriminative stimulus effects in either strain. Results show that a DAT inhibitor alters cocaine-induced behaviors in a strain-dependent manner. These effects may relate to inherent differences in NAc DAT levels between Lewis and F344 rats.

Introduction

Cocaine abuse is a major problem in the United States today, and pharmacotherapy is one treatment approach. Because of the evidence that cocaine exerts many of its behavioral effects by increasing synaptic dopamine (DA) levels [20], [42], many pharmacotherapies have targeted this system. Different approaches have been suggested, such as DA antagonists as blocking agents [22], [27], antidepressants to treat withdrawal-related depressive symptoms, or DA agonists as substitution agents [27]. There are two advantages to a substitution agent: (1) reduction in cocaine use perhaps by blocking “withdrawal” symptomatology such as “craving” that would increase compliance with behavioral treatment interventions [3]; (2) reduction in the effects of cocaine if an addict relapses. Theoretically, cocaine use would be reduced through extinction of the learned contingency between cocaine cues and cocaine reinforcement. An ideal substitution agent would have a slower onset and longer duration of action than cocaine. These characteristics should be associated with low abuse liability, given that the euphoric effects of cocaine are related, in part, to its rapid onset of action [11]. The potential treatment agent needs to be non-toxic, preferably reduce cocaine toxicity, and be acceptable to the addict.

The ability of cocaine to inhibit DA uptake presynaptically, via its actions at the DA transporter (DAT), resulting in an accumulation of DA in the synapse of the nucleus accumbens (NAc) [34] relates to its reinforcing [4], [29] and subjective [37] effects. Accordingly, pretreatment with DA reuptake inhibitors, such as GBR 12909, decreases cocaine self-administration and cocaine-induced reinstatement of responding in rats and primates [12], [31], [33]. However, GBR 12909 only reduced self-administration of high cocaine doses that may reflect rate-disruptive rather than reinforcement reduction effects [31].

Several tropane analogs of cocaine that are potent and selective inhibitors of DAT and have a long duration of action and slow onset have been developed and assessed in rodents and primates. Some of these compounds, such as RTI-31, RTI-32, and RTI-55, substitute for cocaine in a drug discrimination procedure causing minimal disruptions in response rate [2], [7]. Pretreatment with another cocaine analog, RTI-113, causes a downward shift in the cocaine dose–response function in self-administration in rats that could be interpreted as a decrease in cocaine reinforcement [8]. RTI-113 also decreased cocaine self-administration under a second-order schedule of reinforcement in squirrel monkeys [18]. In both rats [8] and monkeys [40], significant effects of RTI-113 on cocaine self-administration were seen under conditions of high levels of DAT occupancy. Recently, a novel phenyltropane analog, 3β-(4-Chlorophenyl) tropane-2β-[3-(4′-methylphenyl) isoxazol-5-yl] Hydrochloride (RTI 336), has been characterized and shown to be a potent and selective DAT inhibitor [5]. At high doses (>3 mg/kg), RTI 336 induces locomotor activity and stereotypy in mice and substitutes for the cocaine discriminative stimulus in rats [5], [6], but its effects on cocaine self-administration have not been assessed.

Inherent differences in DAT levels may exist in individuals prone to drug addiction as suggested by studies in inbred rat strains [21]. Fischer 344 (F344) and Lewis rats differ in acquisition and maintenance of cocaine self-administration [16], [24] and in protein levels in mesolimbic DA system such as tyrosine hydroxylase, glial fibrillary acidic protein (GFAP), neurofilament proteins, and G G-protein-coupled to D2 receptors [10], [15]. Specifically, Lewis rats show enhanced acquisition of cocaine self-administration, compared to F344 rats [24], and lower DAT levels and DA D2 and D3 densities in NAc with no strain differences in D1 densities [10]. Consistent with these mesolimbic DA protein profiles, we showed previously that pretreatment with D1 and D2 agonists (SKF38393, quinpirole) and antagonists (SCH23390, eticlopride) differentially alters cocaine self-administration in these strains [16]. The purpose of this study was to determine whether RTI 336, a potent and selective DAT inhibitor [5], would differentially affect cocaine self-administration in Lewis and F344 inbred rats given the strain differences in NAc DAT levels. We tested the effects of RTI 336 on maintenance of cocaine self-administration under a fixed-ratio schedule of reinforcement and examined its effects on cocaine-induced locomotor activity and drug discrimination.

Section snippets

Subjects

Male Lewis and Fischer 344 inbred rats (Harlan, Indianapolis IN) weighing 300–350 g served as subjects in these studies. Rats were housed singly in stainless-steel, hanging, wire-mesh cages in a temperature- and humidity-controlled colony room maintained on a 12:12 light/dark cycle (lights on at 07:00). Food and water were available ad libitum except during studies utilizing operant responding for food. All procedures were approved by the Institutional Animal Care and Use Committee in

Experiment 1: cocaine self-administration

The effects of RTI 336 on numbers of infusions self-administered across the different cocaine doses are shown in Fig. 1 for both Lewis and F344 rats. The overall three-way interaction of RTI 336 × strain × cocaine dose shows a trend towards significance, F(2,20) = 3.00; P < 0.09. This likely reflects, in part, that the effect of cocaine dose does not differ between strains. Both Lewis and F344 rats self-administer decreasing numbers of infusions across increasing doses of cocaine under baseline

Discussion

The 3-phenyltropane analog, RTI 336, that binds potently and selectively to the dopamine transporter (DAT) [5], leads to more pronounced effects on cocaine self-administration and locomotor activity in Lewis compared to F344 rats. In general, RTI 336 decreases levels of cocaine-induced responding in Lewis rats and increases such responding in F344 rats. These effects of RTI 336 are consistent with known strain differences in protein levels in the mesolimbic dopamine (DA) system [10], [15].

Acknowledgments

This research was supported by SPIRCAP: Novel Pharmacotherapy for Treatment of Cocaine Addiction (NIDA U19 DA133326), the VA New England Mental Illness Research Education and Clinical Center, and by the Yale IWHR Scholar Program on Women and Drug Abuse (1K12DA14038). The authors gratefully acknowledge the technical assistance provided by Diane Lendroth, Adriane Myers, and Hayde Sanchez.

References (42)

  • G. Winger et al.

    Drug-reinforced responding: rapid determination of dose–reponse functions

    Drug and Alcohol Dependence

    (1989)
  • E. Ambrosio et al.

    Behavior genetic investigation of the relationship between spontaneous locomotor activity and the acquisition of morphine self-administration behavior

    Behavioural Pharmacology

    (1995)
  • R.L. Balster et al.

    Preclinical methods for the development of pharmacotherapies for cocaine abuse

  • J. Bergman et al.

    Effects of cocaine and related drugs in nonhuman primates. III: Self-administration by squirrel monkeys

    Journal of Pharmacology and Experimental Therapeutics

    (1989)
  • F.I. Carroll et al.

    Synthesis, monoamine transporter binding properties, and behavioral pharmacology of a series of 3β-(substituted phenyl)-2β-(3′-substituted isoxazol-5-yl)tropanes

    Journal of Medical Chemistry

    (2004)
  • F.I. Carroll et al.

    Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers

    Journal of Medical Chemistry

    (2004)
  • E. Cline et al.

    Stimulus generalization from cocaine to analogs with high in vitro affinity for dopamine uptake sites

    Behavioural Pharmacology

    (1992)
  • S.I. Dworkin et al.

    RTI-113 administration reduces cocaine self-administration at high occupancy of dopamine transporter

    Synapse

    (1998)
  • R.W. Foltin et al.

    Smoked and intravenous cocaine in humans: acute tolerance, cardiovascular and subjective effects

    Journal of Pharmacology and Experimental Therapeutics

    (1991)
  • J.R. Glowa et al.

    Effects of dopamine reuptake inhibitors on food- and cocaine-maintained responding: I. Dependence on unit dose of cocaine

    Experimental and Clinical Psychopharmacology

    (1995)
  • X. Guitart et al.

    Fischer and Lewis rat strains differ in basal levels of neurofilament proteins and their regulation by chronic morphine in the mesolimbic dopamine system

    Synapse

    (1992)
  • Cited by (0)

    View full text